Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 33
Significant growth opportunities fuelled by strong pipeline
across all four strategic focus areas
PHASE 1
NN1436 LAI287
NN1406
PI406
NN9030 G530L
1
NN9838 Amylin analogue
1
NN9747
NN9277
NN9499
NN9423
-
NN7170
-
PYY analogue
GG-co-agonist
FGF21 obesity
Tri-agonist 1706
Sc N8-GP
PHASE 2
Anti-IL-21 and liraglutide
Semaglutide obesity
Concizumab
Semaglutide NASH
PHASE 3
Oral semaglutide
SUBMITTED
APPROVED
Semaglutide - QW GLP-1
LevemirⓇ
N8-GP Long-acting rFVIII
Somapacitan - QW GH1
-
NovoRapidⓇ
NovoMix®
Tresiba®
RyzodegⓇ
XultophyⓇ
VictozaⓇ
Fiasp®
SaxendaⓇ
NovoSevenⓇ
NovoEight®
NovoThirteenⓇ
RebinynⓇ/RefixiaⓇ2
Norditropin®
Diabetes
Obesity
Haemophilia
Growth disorders
Other serious chronic diseases
1 Study conducted in adult growth hormone disorder 2 RebinynⓇ is the brand name in the US and Refixia® in the EU
QW: Once-weekly; GG: Glucagon GLP-1; Sc: Subcutaneous; QD: Once daily; GH: Growth hormone
changing
diabetes
novo nordiskView entire presentation